Puma Biotechnology, Inc. (PBYI) Q3 2026 earnings results
Puma Biotechnology, Inc. (PBYI) reported Q3 2026 results on Nov 5, 2026, 4:13:18 PM ET: adjusted EPS $0.15 vs. $0.12 expected (beat by 25.0%); revenue $55.10M vs. $0 expected (beat by $55.10M). Outlook: The company provided updated full-year 2026 guidance for total revenue of $224–$227 million and net income of $20–$22 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $0.15 | $0.12 | Beat by 25.0% |
| Revenue | $55.10M | $0 | Beat by $55.10M |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:13:18 PM ET. Nexqual published them 40 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 1.1% from $54.48M.
Stock reaction
The results came out after the market closed. PBYI closed at $8.25 on November 6, 2026, down 15.6% from its $9.77 close on November 5, 2026 before the results. Latest: $8.07 as of 11:39 AM ET, −17.4% since the pre-release close.
Questions and answers
Did Puma Biotechnology, Inc. beat earnings expectations?
Yes. Puma Biotechnology, Inc. reported adjusted EPS of $0.15 against an average analyst estimate of $0.12 (beat by 25.0%), and revenue of $55.10M against $0 expected (beat by $55.10M).
What were Puma Biotechnology, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $0.15 and revenue of $55.10M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 1.1% from $54.48M.
When did Puma Biotechnology, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:13:18 PM ET, in an SEC 8-K filing (Item 2.02).
How did PBYI stock react to the earnings?
The results came out after the market closed. PBYI closed at $8.25 on November 6, 2026, down 15.6% from its $9.77 close on November 5, 2026 before the results. Latest: $8.07 as of 11:39 AM ET, −17.4% since the pre-release close.
What did Puma Biotechnology, Inc. say about its outlook?
The company provided updated full-year 2026 guidance for total revenue of $224–$227 million and net income of $20–$22 million.
More on PBYI
PBYI stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:39 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt